Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D05STQ
|
|||
| Drug Name |
Pazufloxacin
|
|||
| Synonyms |
127045-41-4; T-3761; UNII-4CZ1R38NDI; 4CZ1R38NDI; NCGC00167534-01; DSSTox_CID_26697; DSSTox_RID_81831; DSSTox_GSID_46697; Pazufloxacin [INN]; SMR000466380; CCRIS 7312; CAS-127045-41-4; T 3761; 127046-18-8; PZFX; Pazufloxacin (JAN/INN); SCHEMBL34460; 7H-Pyrido(1,2,3-de)-1,4-benzoxazine-6-carboxylic acid, 10-(1-aminocyclopropyl)-9-fluoro-2,3-dihydro-3-methyl-7-oxo-, (S)-; MLS000759513; MLS001424116; CHEMBL240163; DTXSID5046697; CHEBI:94700; HY-B0724B; HMS2051B05; HMS2090H07; BCP12954; LSM-5745; RKL10069; ZINC3779726; Tox21_112531; BDBM50248017; MFCD00865012; AKOS015900451; Tox21_112531_1; AC-3506; CCG-100919; DB11774; GM-1171; KS-5008; NC00169; NCGC00167534-02; (-)-(3S)-10-(1-Aminocyclopropyl)-9-fluoro-2,3-dihydro-3-methyl-7-oxo-7H-pyrido(1,2,3-de)-1,4-benzoxazine-6-carboxylic acid; 7H-Pyrido(1,2,3-de)-1,4-benzoxazine-6-carboxylic acid, 2,3-dihydro-10-(1-aminocyclopropyl)-9-fluoro-3-methyl-7-oxo-, (S)-; AB0012715; D01153; AB00639918-07; AB00639918-09; AB00639918_10; Pazufloxacin, VETRANAL(TM), analytical standard; SR-01000759348; J-005457; Q3898423; SR-01000759348-4; (S)-10-(1-aminocyclopropyl)-9-fluoro-3-methyl-7-oxo-3,7-dihydro-2H-[1,4]oxazino[2,3,4-ij]quinoline-6-carboxylic acid; (S)-10-(1-aminocyclopropyl)-9-fluoro-3-methyl-7-oxo2,3-dihydro-7H-pyrido[1,2,3-de][1,4]benzoxazine-6-carboxylic acid; 7H-Pyrido[1,2,3-de]-1,4-benzoxazine-6-carboxylic acid,10-(1-aminocyclopropyl)-9-fluoro-2,3-dihydro-3-methyl-7-oxo-, (3S)-; 7H-Pyrido[1,2,3-de]-1,4-benzoxazine-6-carboxylicacid,10-(1-aminocyclopropyl)-9-fluoro-2,3-dihydro-3-methyl-7-oxo-
Click to Show/Hide
|
|||
| Drug Type |
Small molecular drug
|
|||
| Indication | Conjunctivitis [ICD-11: 9A60; ICD-9: 372] | Phase 3 | [1] | |
| Structure |
 |
Download2D MOL |
||
| Formula |
C16H15FN2O4
|
|||
| Canonical SMILES |
CC1COC2=C3N1C=C(C(=O)C3=CC(=C2C4(CC4)N)F)C(=O)O
|
|||
| InChI |
1S/C16H15FN2O4/c1-7-6-23-14-11(16(18)2-3-16)10(17)4-8-12(14)19(7)5-9(13(8)20)15(21)22/h4-5,7H,2-3,6,18H2,1H3,(H,21,22)/t7-/m0/s1
|
|||
| InChIKey |
XAGMUUZPGZWTRP-ZETCQYMHSA-N
|
|||
| CAS Number |
CAS 127045-41-4
|
|||
| PubChem Compound ID | ||||
| ChEBI ID |
CHEBI:94700
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Bacterial DNA gyrase (Bact gyrase) | Target Info | Inhibitor | [2] |
| Bacterial DNA topoisomerase 4A (Bact parC) | Target Info | Inhibitor | [2] | |
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT03696342) Efficacy of the Ophthalmic Pazufloxacin 0.6% for Bacterial Conjunctivitis, Compared to Gatifloxacin 0.3%. (PRO-157). U.S. National Institutes of Health. | |||
| REF 2 | Target preference of 15 quinolones against Staphylococcus aureus, based on antibacterial activities and target inhibition. Antimicrob Agents Chemother. 2001 Dec;45(12):3544-7. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.